The primary function of the Protocol Review and Monitoring System is to ensure that all human subjects research is of the highest scientific merit and proceeds at an optimal pace. Over the past 5 years, 934 faculty members participating in human subjects research utilized the PRMS, and 273 new interventional protocols were reviewed by the PRMS in the last year. The PRMS is supported by 32 staff members under the direction of Dr. Aman Buzdar, Vice President for Clinical Research Administration. The core function of the PRMS is to provide a mechanism to ensure adequate internal oversight of the scientific and research aspects of all institutional clinical trials through a rigorous review of the scientific merit, progress, and priorities of the clinical research protocols conducted by the faculty. This function is coordinated by the PRMS as a single source of service, support and oversight The PRMS is made up of several subcommittees (described below) that are designated to provide scientific review and approval for new research protocols, as well as to monitor the progress of the ongoing trials. Importantly, the increasingly complex regulatory requirements and oversight activities have resulted in increased institutional staffing commitments and prompted provision of several new or expanded services, as described in greater detail in this application. During the last grant year, the funds used to support the PRMS function were $240,152 (8%) from the Cancer Center Support Grant (CCSG), $110,000 (4%) from IRB fees, and $2,540,868 (88%) from the institution. It is projected that in the next award cycle, the funds used to support the PRMS function will be $249,758 provided by the CCSG (9%), $110,000 from IRB fees (4%), and $2,406,755 (87%) from the institution. The PRMS consists of four Clinical Research Committees (CRCs) and one Psychosocial Behavioral Health Services Research Committee (PBHSRC) that review protocols for scientific merit. The Chairs of these committees are also members of the Electronic Protocol Accrual Auditing Committee (ePAAC) that selects and monitors all institutional protocols that are identified as slow-accruing. Eight hundred and one protocols were reviewed by ePAAC in the last fiscal year, and 115 (14%) were closed or withdrawn. During the last 6 months, substantive changes have been made 1) to make the initial review and prioritization of protocols by the CRC and the disease site programs and departments more rigorous, 2) to reduce the time required for review, and 3) to scrutinize accrual more carefully.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016672-38
Application #
8557388
Study Section
Subcommittee G - Education (NCI)
Project Start
1998-09-04
Project End
2018-06-30
Budget Start
2013-09-06
Budget End
2014-06-30
Support Year
38
Fiscal Year
2013
Total Cost
$325,951
Indirect Cost
$122,271
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :
Patel, V K; Lamothe, B; Ayres, M L et al. (2018) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32:920-930
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid et al. (2018) Phase 3 results for vosaroxin/cytarabine in the subset of patients ?60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica 103:e514-e518
Assi, Rita; Kantarjian, Hagop M; Kadia, Tapan M et al. (2018) Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124:2758-2765
Yam, Clinton; Murthy, Rashmi K; Valero, Vicente et al. (2018) A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36:299-306
Lacourt, Tamara E; Vichaya, Elisabeth G; Escalante, Carmen et al. (2018) An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology 96:109-117
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433

Showing the most recent 10 out of 12418 publications